CSR Electrolyte Management in Renal Disease 1 — Questions and Answers

Question 1: A hemodialysis patient presents with a pre-dialysis serum potassium of 7.0 mEq/L and ECG changes (peaked T waves, widened QRS). Which food should be IMMEDIATELY eliminated from the diet?

White rice and pasta
Bananas, oranges, potatoes, and tomatoes (Correct answer)
Chicken breast and fish
White bread and crackers

Correct answer: Bananas, oranges, potatoes, and tomatoes

Bananas, oranges, potatoes, and tomatoes are among the highest-potassium foods. At K+ 7.0 mEq/L with ECG changes (life-threatening), eliminating these high-potassium foods immediately is critical, though medical management (IV calcium, insulin/glucose) takes priority.

High-potassium foods (>200 mg per serving) that must be restricted in severe hyperkalemia include: bananas (~422 mg/medium), oranges (~237 mg/medium), orange juice (~496 mg/8 oz), potatoes (~900 mg/medium baked), tomatoes/tomato products (~400–1000 mg/cup), avocados (~975 mg/medium), cantaloupe (~427 mg/cup), dried fruits (prunes, raisins ~500–800 mg/quarter cup), nuts/seeds (~200–400 mg/oz), milk/yogurt (~350–450 mg/cup). Salt substitutes (NoSalt, Nu-Salt) contain 2500–3000 mg potassium per teaspoon and must be explicitly forbidden. In dialysis patients, potassium restriction to <2000 mg/day is standard. White rice, pasta, and white bread are low-potassium and generally unrestricted.

Question 2: In managing dietary phosphorus in CKD, which type of dietary phosphorus has the LOWEST bioavailability and is therefore least harmful?

Inorganic phosphate from food additives (phosphoric acid, sodium phosphate)
Organic phosphate from animal sources (meat, dairy, fish)
Organic phosphate from plant sources bound to phytate (Correct answer)
All forms of phosphate are equally bioavailable

Correct answer: Organic phosphate from plant sources bound to phytate

Plant-derived phytate-bound phosphorus has the lowest bioavailability (~20–40%) because humans lack intestinal phytase to cleave phytate. Animal-source phosphorus is 40–60% bioavailable, while inorganic phosphate additives are nearly 100% bioavailable.

Phosphorus bioavailability hierarchy: Inorganic (food additive) phosphate ~100% → Animal-source organic phosphate ~40–60% → Plant-source phytate-bound phosphate ~20–40%. Inorganic phosphate additives (sodium phosphate, polyphosphates, phosphoric acid in colas) are used extensively in processed foods as preservatives, emulsifiers, and flavor enhancers. Phytate in grains, legumes, seeds, and nuts binds phosphorus in a form humans cannot digest (lacking intestinal phytase); however, gut bacteria in the colon can cleave phytate, partially releasing phosphorus. This bioavailability difference justifies dietary advice to choose whole, unprocessed plant foods over processed/packaged foods for CKD patients, even when the total phosphorus content appears similar on food labels.

Question 3: A peritoneal dialysis patient has persistent hypomagnesemia (Mg 1.4 mEq/L). Which dietary counseling is appropriate?

Restrict all magnesium-containing foods as magnesium accumulates in dialysis
Encourage adequate intake of magnesium-rich foods (nuts, seeds, legumes, whole grains) and consider oral magnesium supplementation after physician review (Correct answer)
Recommend magnesium-containing laxatives freely as they are safe in PD
Hypomagnesemia is not clinically significant in renal patients

Correct answer: Encourage adequate intake of magnesium-rich foods (nuts, seeds, legumes, whole grains) and consider oral magnesium supplementation after physician review

PD patients can lose magnesium into dialysate, and dietary restriction of magnesium-rich foods (often also high in potassium/phosphorus) can cause hypomagnesemia. Low magnesium increases risk of cardiac arrhythmias, insulin resistance, and cardiovascular events in CKD.

Unlike HD patients who often have normal or elevated magnesium (dialysate contains ~0.5 mEq/L Mg), PD patients may develop hypomagnesemia due to continuous dialysate magnesium losses and dietary restriction of Mg-rich foods (which are often also high in potassium/phosphorus). Hypomagnesemia in CKD is associated with: increased cardiovascular mortality, progression of CKD (Mg inhibits vascular calcification), insulin resistance, and muscle cramps. Magnesium-rich foods: nuts (almonds, cashews), seeds (pumpkin, sunflower), legumes, whole grains, dark chocolate, avocado. Oral supplementation (magnesium oxide, magnesium citrate) should be done under physician supervision to avoid hypermagnesemia. Caution: magnesium-containing antacids (Maalox, Mylanta) and laxatives (Milk of Magnesia) can cause dangerous hypermagnesemia in ESRD.

Question 4: Which clinical condition is MOST associated with hyponatremia in CKD patients and is directly managed through fluid restriction?

Dehydration from excessive sweating
Dilutional hyponatremia from fluid overload and impaired free water excretion (Correct answer)
Hyperaldosteronism causing sodium retention
Excessive dietary sodium intake

Correct answer: Dilutional hyponatremia from fluid overload and impaired free water excretion

In advanced CKD and dialysis patients, impaired free water excretion leads to dilutional hyponatremia when fluid intake exceeds excretory capacity. Fluid restriction (not sodium supplementation) is the primary treatment.

Dilutional hyponatremia in CKD occurs when obligatory fluid intake (thirst, medications, foods) exceeds the kidney's reduced capacity to excrete free water. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) can co-occur in hospitalized CKD patients. Clinical manifestations: nausea, headache, confusion, seizures (Na < 120 mEq/L). Management: fluid restriction (often 500–1000 mL/day for anuric HD patients) to allow serum sodium to rise. Avoid rapid correction (>6–8 mEq/L/24 hours) to prevent osmotic demyelination syndrome (central pontine myelinolysis). Dietary counseling includes: tracking all fluid sources (soups, gelatins, ice cream, frozen fruit), using small cups, chewing gum and citrus candy for thirst relief. In HD patients, the dialysate sodium concentration can be adjusted to facilitate sodium/fluid management.

Question 5: The dialysis patient's 'dry weight' is a critical parameter in managing fluid and sodium balance. How is dry weight BEST defined?

The patient's weight after a full night's sleep without eating
The lowest weight a patient can tolerate at the end of dialysis without symptoms of hypotension or cramping, representing euvolemic status (Correct answer)
The ideal body weight calculated from standard height-weight tables
The pre-dialysis weight minus 2 kg

Correct answer: The lowest weight a patient can tolerate at the end of dialysis without symptoms of hypotension or cramping, representing euvolemic status

Dry weight (target weight or euvolemic weight) is the post-dialysis weight at which the patient is as close to euvolemia as possible — neither fluid-overloaded nor fluid-depleted — determined clinically by blood pressure, absence of edema, and absence of hypotension/cramping during UF.

Dry weight in HD is the target end-dialysis weight representing euvolemia. Clinical assessment: absence of edema, normal blood pressure off antihypertensives, no hypotension/cramping during ultrafiltration. Methods to assess dry weight: clinical examination (JVP, lung auscultation), bioimpedance analysis (BIA — direct extracellular water measurement), lung ultrasound (B-lines indicating pulmonary edema), inferior vena cava diameter. Nutritional implications: changes in appetite, weight loss from PEW, or weight gain from muscle building all require dry weight re-assessment. Ideally, interdialytic weight gain should be ≤ 1 kg/day (≤ 2–3 kg between sessions). Educating patients on sodium restriction as the primary driver of thirst and fluid intake is a key dietitian role.

Question 6: Calcium-phosphate product (Ca × P) is monitored in dialysis patients to assess risk of vascular calcification. What product value is generally associated with increased calcification risk?

Ca × P > 35 mg²/dL²
Ca × P > 55 mg²/dL² (Correct answer)
Ca × P > 75 mg²/dL²
Ca × P > 20 mg²/dL²

Correct answer: Ca × P > 55 mg²/dL²

A calcium-phosphate product > 55 mg²/dL² (older KDOQI threshold) is associated with increased risk of metastatic/vascular calcification (coronary arteries, heart valves, soft tissues) in dialysis patients. KDIGO 2017 moved away from strict targets but risk increases above this value.

The solubility product of calcium and phosphorus in physiological fluids: when Ca × P (in mg/dL) exceeds approximately 55–70 mg²/dL², calcium phosphate crystals begin to precipitate in soft tissues — vascular calcification, periarticular calcification, calcinosis cutis, and calciphylaxis. Example: serum calcium 9.5 mg/dL × phosphorus 6.5 mg/dL = 61.75 mg²/dL² (above threshold). KDOQI 2003 set target < 55 mg²/dL²; KDIGO 2017 moved to 'treat the individual variables toward normal' rather than product targets. Management: phosphate restriction, non-calcium-containing phosphate binders (sevelamer reduces cardiovascular calcification in RCTs), calcium-containing binder restriction (limit to 1.5 g elemental calcium/day from binders), active vitamin D analog minimization in patients with hypercalcemia.

CSR Electrolyte Management in Renal Disease 1

A hemodialysis patient presents with a pre-dialysis serum potassium of 7.0 mEq/L and ECG changes (peaked T waves, widened QRS).
Which food should be IMMEDIATELY eliminated from the diet?